Immunostimulant activities of muramyl dipeptide (enhancement of specific immune responses and of nonspecific resistance to infection) were retained by its N-acetylmuramyl-L-alanyl-D-glutaminyl-n-butyl ester derivative, although very large amounts administered intravenously, or even by the very sensitive intracerebroventricular route, did not elicit fever in the rablit. This analog also appeared to be devoid of other secondary effects which have been observed after administration of muramyl dipeptide.
N-Acetylmuramyl-L-alanyl-D-isoglutamine (also called muramyl dipeptide [MDP] ) represents the minimal structure that can replace whole mycobacterial cells in Freund complete adjuvant (3, 7, 10) , although it is devoid of several secondary effects inherent to bacterial adjuvants (2) . MDP has been shown to be also the smallest moiety capable of inducing changes in body temperature (12, 13) . By the intravenous route, the minimal pyrogenic doses for MDP and lipopolysaccharide (LPS) in rabbits are, respectively, 25 ,ug/kg and 1.65 ng/kg. When administered by the intracerebroventricular route, a 200,000-fold-smaller dose of MDP is sufficient to elicit fever (19) , whereas a 200-fold-smaller dose of LPS is required (9, 20) . In spite of what has been assumed in the first studies (12) , the immunostimulating effects of synthetic MDP do not appear closely linked to pyrogenicity. The febrile response can be inhibited by indometha4ih, although neither the adjuvant activity nor the nonspecific stimulation of resistance to infection was impaired by this treatment under sitmilar conditions (17) . Moreover, several adjuvant-active MDP derivatives have been found devoid of pyrogenicity (P. Lefrancier, M. Derrien, X. Jamet, J. Choay, E. Lederer, F. Audibert, M. Parant, F. Parant, and L. Chedid, J. Med. Chem., in press), and nonpyrogenic compounds which stimulate resistance to infection without enhancing the specific immune response have also been obtained (15) .
In this paper, we report studies concerning an MDP analog, its N-acetylmuramyl-L-alanyl-Dglutaminyl-n-butyl ester derivative [MDP(Gln)-OnBul, which was found devoid of any pyrogenic activity after an intravenous injection of 10 mg/kg (Lefrancier et al., J. Med. Chem., in press). Our data show that even when administered by the very sensitive intracisternal route, this derivative was found to be at least 105-fold less pyrogenic than MDP. Contrary to MDP, it did not elicit the production of endogenous pyrogen in vivo or in vitro, although it displayed equally strong immunostimulant properties.
MATERIALS AND METHODS Synthetic compounds. MDP was MDP-Pasteur (Institut Pasteur Production, Paris). The synthesis of MDP(Gln)-OnBu has been reported elsewhere (Lefrancier et al., in press). Optical rotation was {a}D' = +350 (c = 1 in acetic acid). Elemental analysis was as follows: found, C, 49.5%; H, 7.4%; N, 10.0%; 0, 33.0%o; calculated for C23H40N4011 * 0.5 H20 (557.6), C, 49.5%; H, 7.6%; N, 9.9%o; 0, 32.7%). The compound is homogeneous on thin-layer chromatography (Merck silica gel 60 plates), with the following solvent system (volume/volume): n-butanol-pyridine-acetic acid-water (30:20:6:24); n-butanol-acetic acid-water (4:1:5; upper phase); ethyl acetate-pyridine-acetic acid-water (5:5:1:3). The compound is also homogeneous on high-pressure liquid chromatography (Spherisorb 5-ODS column, 250 by 4.7 mm) with 0.005 M ammonium acetate (pH 5.0 with hydrochloric acid)-acetonitrile (85:15, vol/vol) solvent system as a mobile phase.
Animals. Except in toxicity experiments in which DBA/2 female mice were used, Swiss female mice (Iffa Credo, Lyon, France) were used throughout this study; unless otherwise mentioned, they were 6 to 8 weeks old. Young male Wistar rats weighing 80 to 100 g were obtained from Iffa Credo, and male Hartley guinea-pigs weighing 300 to 400 g were obtained from Coblanbel (Roger Bellon, Paris). New Zealand male rabbits weighing 2.5 kg were obtained from Evic Ceba (Paris).
Adjuvant activity. Bovine serum albumin (BSA) fraction V was purchased from Pentex, and ovalbumin (Sx crystallized) was purchased from Miles Labora-417 on October 19, 2017 by guest http://iai.asm.org/ Downloaded from tories (Elkhart, Ind.). DT-Vax was a commercial diphtheria-tetanus vaccine (Institut Merieux, Lyon, France). Tetanus and diphtheria toxins were kindly provided by D. Labert (Institut Pasteur Production). Diphtheria toxin was repurified by passage through a column of DEAE-cellulose (DE52) by the procedure described previously (14) .
Ovalbumin was administered to guinea pigs as a water-in-oil emulsion (1:1, vol/vol) with Freund incomplete adjuvant, purchased from Difco Laboratories, Detroit, Mich. In experimental groups, synthetic adjuvants were added to saline. Antibody responses and delayed-type hypersensitivity were tested 3 weeks later by previously published procedures (3) .
The enhancement of response to BSA after administration of adjuvant and antigen in saline was evaluated as previously described (1) in either adult or old mice. Antibody titers obtained during primary and secondary responses were measured by passive hemagglutination with sheep erythrocytes (SRBC) coated with BSA.
Responses to toxoids were evaluated after administration of adjuvant and antigen in saline. Mice were injected subcutaneously, and guinea pigs were injected intradermally in both hind footpads. Antigenic preparations were DT-Vax in saline either alone or with adjuvants [aluminium hydroxyde, MDP, or MDP(Gln)-OnBu]. Animals were boosted with antigen alone. Humoral response to each antigen was tested separately by passive hemagglutination of toxin-coated SRBC. Toxins [kept in half-saturated (NH4)2SO4] were exhaustively dialyzed against phosphate-buffered saline (PBS) (0.067 M, pH 7) containing lysine 0.025 M. The final concentration was approximately 2 mg of toxin in 1 ml of buffer. SRBC were washed three times in 0.01 M PBS (pH 7). Diphtheria or tetanus toxin was gently mixed with 0.5 ml of packed SRBC, and 0.1 ml of glutaraldehyde (25%) was added. The mixture was stirred for 30 min at room temperature. Coated SRBC were washed twice in 0.01 M PBS and once in the same buffer containing 1% normal rabbit serum preabsorbed with fresh SRBC.
Protective activity against KiebsieUa infection. A Klebsiella pneumoniae strain of capsular type 2 (Institut Pasteur Collection no. 7832) was used in this study as in previous ones (5) . MDP or its derivative was administered in saline 24 h before the bacterial challenge, and survivors were recorded for 15 days, since in all of our experiments no deaths from Klebsiella infection were observed after this period. The P values were obtained by the adjusted chi-square method (21) .
Seven-day-old mice raised in our animal care facility were mixed at random, redistributed in litters of usually eight or nine per mother, and treated with glycopeptides by the subcutaneous route. Adult splenectomized mice were operated either at 7 days of age or 1 week before the challenge. Splenectomy was carried out under ether anesthesia, and spleens were removed through a left subcostal incision. The body wall and the skin were closed with separate layer using catgut, and in young animals the wound was carefully wiped with wet tissue.
Toxicity measurements. Toxicity of LPS or glycopeptides administered separately was evaluated in 5-week-old mice which had been adrenalectomized 48 h before being challenged intravenously with various doses of these compounds (4) . Toxic synergism was evaluated in mice or in guinea-pigs by simultaneously injecting Salmonella enteritidis LPS or killed Pseudomonas aeruginosa cells, with or without glycopeptide. LPS prepared by the phenol-water procedure was purchased from Difco. P. aeruginosa (Institut Pasteur Collection no. A 237) was grown for 48 h and killed by heating at 60°C for 1 h. Sterility of the various preparations was checked. Deaths were recorded for 48 h after injection.
Limulus amoebocyte lysate tests. The Limulus amoebocyte lysate test was performed according to established techniques by comparison with several dilutions of Escherichia coli 0113 LPS obtained from the Bureau of Biologics (Rockville, Md.).
Rabbit pyrogen assay. All glassware, needles, syringes, and PBS were pyrogen free. Procedures used in selecting rabbits and in recording temperatures were similar to those previously reported (17) . Intravenous injections were made via the marginal ear vein with solutions prewarmed to 37°C, particularly in the case of plasma transfer (10 mi/kg). Intracerebroventricular injections were made in a constant volume of 20 ,ul/kg through a cannula permanently inserted into the right lateral ventricle (19) . In plasma transfer studies, donors were exsanguinated under ether anaesthesia and plasma dialyzed overnight at 4°C before being injected to normal recipient rabbits (17) . Results are expressed as the mean ± standard deviation of the maximal change in rectal temperature recorded for 5 h after injection.
Leukocyte counts. Leukocyte counts were made with an electronic particle counter (Coultronics, Margency, France), and differential cell counts were made with stained smears of blood samples collected from a marginal ear vein (17) .
RESULTS
Adjuvant activity of MDP(Gln)-OnBu. To In the following experiments, the adjuvants were administered in saline with different protein antigens either to mice (Tables 1 through 4) , or to guinea pigs (Table 5 ). Like MDP, MDP(Gln)-OnBu given in saline clearly enhanced both primary and secondary humoral responses in adult mice (Table 1) .
A similar experiment was performed in 19-month-old mice. No primary or secondary responses were observed in the control group. (Table 2) .
In the following experiments, a commercial vaccine containing both tetanus and diphtheria toxoids, DT-Vax, was administered to mice either alone or with one of the following adjuvants: MDP, MDP(Gln)-OnBu, or A1203. The results in Table 3 show that both MDP and its derivative enhanced the secondary response against both toxoids as effectively as aluminium hydroxide.
Separate experiments were performed in mice using 10 ,ug of MDP(Gln)-OnBu with DT-Vax at 10-fold dilutions, the dosages being, respectively, 0.5, 0.05, and 0.005 limit of floculation for tetanus toxoid and 2.5, 0.25, and 0.025 limit of floculation for diphtheria toxoid. In all cases, the titers of antibodies in experimental groups were significantly higher than in the controls, both for primary and secondary responses (Table 4) .
Adjuvant activity was also tested in guinea pigs by using the higher concentration of vaccine either alone or with MDP, MDP(Gln)-OnBu, or A1203. The results in Table 5 show that both glycopeptides enhanced the secondary response, again as effectively as aluminium hydroxide.
Protective activity against K. pneumoniae infection. Several experimental models were used to demonstrate nonspecific stimulation by MDP(Gln)-OnBu in animals subsequently infected with Klebsiella. The doses and time schedule were the same as those shown previously to be the most efficient with MDP (5).
In normal adult mice, both MDP and MDP(Gln)-OnBu had the same activity and were able to protect more than 50% of the treated animals ( Table 6 ). Although removal of the spleen from adult mice 1 week before the challenge did not modify their resistance (same 50% lethal dose as in normal adults), the susceptibility to this infection was increased a 1,000-fold when adult animals had been splenectomized at day 7 after birth. Nevertheless, MDP and MDP(Gln)-OnBu were still effective under these conditions (Table 6 ). In another assay, young mice were used. They were infected by the subcutaneous route since after an intravenous challenge deaths occur more rapidly (in less than 24 h) than in adults. MDP(Gln)-OnBu appeared somewhat more effective than MDP when given subcutaneously. If the glycopeptides were given directly by the intragastric route to these animals, no differences were observed; a significant protection was obtained with both compounds (Table 6 ). Since administration of LPS in young mice by the oral route or even by the subcutaneous route is devoid of any protective effect (16) , the present results show that the activity of the glycopeptides cannot be attributed to some endotoxic contamination. The last example given in Table 6 demonstrates that rats also could be effectively protected against Klebsiella infection by both molecules. In this experiment, 100 p.g of MDP and a 1,000 ,ug of MDP(Gln)-OnBu were administered because of the relatively high body weight of rats.
Toxicity determination studies. In contrast to other immunostimulants such as BCG or LPS, Previous experiments have shown that, whereas an intravenous injection of 0.1 ,ug of LPS killed 100% of adrenalectomized mice, all animals survived after the injection of 0.5 mg (highest dose tested) of MDP (14) . In comparative experiments, MDP(Gln)-OnBu was also shown to be devoid of toxicity in adrenalectomized mice (100 per cent survival after intravenous injection of 500 ,ug per mouse).
More recently, a toxic synergism has been reported in strain 2 guinea pigs which were given simultaneously a combination of MDP and either LPS or Pseudomonas vaccine by the intravenous route (18) . In the following assays, outbred Hartley guinea pigs were also given either LPS or killed Pseudomonas with MDP or a Protection is the difference between percentages of survivors in the treated group and in its control group. All the cumulative results mentioned in this column are highly significant (P < 0.01) as calculated by the adjusted chi-square method. b i.V., Intravenous route. c Adult mice which had been splenectomized one week before challenge. d Adult mice which had been splenectomized at 7 days of age. e s.c., Subcutaneous route. f i.g., Intragastric route. following fever studies in the rabbit. The capacity of high doses of MDP and of several of its derivatives to induce gelation of Limulus amoebocyte lysate has been previously described (11) , although no real correlation was found between this ability and pyrogenicity (unpublished results). For MDP, the minimal positive concentration was 250 ,ug/ml (as compared with 0.1 ng/ml for LPS), whereas MDP(Gln)-OnBu was still negative at 1 mg/ml.
Whereas MDP-treated rabbits respond with a marked increase in temperature at the dose of 30 ,ug/kg (6) , no febrile response was observed in all groups of three rabbits which received various doses of MDP(Gln)-OnBu by the intravenous route, the largest dose used being 10 mg/kg (data not shown). At the peak of the MDP-induced febrile response, plasma transfer experiments demonstrated the presence of circulating endogenous pyrogen (19) . Comparable assays were performed under the same conditions by injecting to normal recipients plasma collected from donor rabbits treated with 300 ,ug of MDP or of the derivative per kg. Only plasma from MDPtreated rabbits was able to produce a febrile reaction in recipients (Fig. 1) . Plasma samples from normal donors or from donors which had received MDP(Gln)-OnBu were inactive. In another study, it was shown that this same derivative does not produce endogenous pyrogen in vitro although it can still produce lymphocyte activating factor (C. Damais, G. Riveau (Fig. 2) . Influence of MDP(Gln)-OnBu on blood leukocyte counts. Like other exogenous pyrogens, MDP causes an immediate drop in the total number of circulating leukocytes (12) ; all populations (granulocytes, lymphocytes, and monocytes) are affected (17) . The influence of MDP(Gln)-OnBu on circulating leukocytes was evaluated under the same conditions. Animals were always given the compound to be tested at 10:00 a.m. to avoid differences related to circadian rhythms (8) . PBS-treated controls (data not shown) did not show significant modifications during the same period (see reference 17) . Cumulative results show that no decrease occurred in the total blood counts of rabbits treated by the MDP derivative (Fig. 3) . Differential cell counts indicate, however, that 3 or 4 h after injection there was an increase in the granulocyte count compensated by a decrease of lymphocyte number ( Fig. 3a and b) . Curiously, the total number of monocytes was not modified after injection of the MDP analog, whereas after MDP this population was severely decreased at all times, even at 24 h, the time at which the granulocyte number returned to normal (Fig. 3c) .
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DISCUSSION
The data reported here demonstrate that the MDP(Gln)-OnBu analog retained all the immunostimulant activities of MDP, although it had no detectable pyrogenicity. This derivative was effective as an adjuvant when injected with protein antigens in saline to adult or to old mice and also to guinea pigs. Stimulation of nonspecific immunity (as demonstrated by increased resistance to Klebsiella infection) was similar to that observed with MDP. The nonpyrogenic analog was capable of protecting newborn and adult mice or rats. It even protected mice rendered highly susceptible to this bacterial challenge by previous neonatal splenectomy. Like MDP, the derivative did not induce lymphoid hyperplasia, and contrary to MDP, it did not enhance endotoxic lethality, at least to the same degree.
The most interesting finding was that, in contrast to MDP, this molecule did not elicit fever in rabbits and did not produce endogenous pyrogen in vivo. The absence of pyrogenicity was clearly established by injecting the glycopeptide by the intracerebroventricular route which enhances tremendously the susceptibility of rabbits to MDP. Whereas less than 1 ng of MDP per kg elicits a febrile response, no pyrogenicity was detectable after administration of more than a 100,000-fold-larger dose of the derivative by the same route. Although MDP(Gln)-OnBu does not produce endogenous pyrogen in vitro, it was able to induce strong lymphocyte-activating factor activity in the supematant of rabbit or human cell cultures (Damais et al., submitted for publication).
